Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Scientific Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,227 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 1,452 · Balance 118,679 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2026-09-01 · Sale · Disposed 1,452 · Balance 117,227 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2029-08-28 | Direct | 60,858 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 1,452 · Balance 60,858 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · derivative · entry 5 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,207 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · derivative · entry 4 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 Underlying: Common Stock · 3,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:26 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,884 | $9.65 | $18,189.45 |
DisclosureSEC source: 0001209191-23-043975 · doc4.xml · nonDerivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,955 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.61 and the highest price at which shares were sold was $9.82. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:26 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043975 · doc4.xml · derivative · entry 5 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:26 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,207 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043975 · doc4.xml · derivative · entry 4 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,068 Underlying: Common Stock · 3,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:26 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043975 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:26 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043975 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 2, 2023 20:31 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,136 | $9.88 | $11,219.48 |
DisclosureSEC source: 0001209191-23-026515 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,632 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. F1 · balance_after: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| April 30, 2023 Filed May 2, 2023 20:31 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026515 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,275 Underlying: Common Stock · 3,206 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2023 Filed May 2, 2023 20:31 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026515 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009708 · doc4.xml · derivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 88,900 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001209191-23-009708 · doc4.xml · derivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,900 Underlying: Common Stock · 88,900 shares Expires 2033-02-13 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,207 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005904 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,481 Underlying: Common Stock · 3,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,412 | $11.78 | $16,632.80 |
DisclosureSEC source: 0001209191-23-005904 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,009 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005904 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 23:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,165 | $12.88 | $15,005.78 |
DisclosureSEC source: 0001209191-22-055138 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,214 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.76 and the highest price at which shares were sold was $12.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 23:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,207 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055138 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,688 Underlying: Common Stock · 3,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 23:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055138 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 60,298 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001209191-22-045192 · doc4.xml · derivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,298 Underlying: Common Stock · 60,298 shares Expires 2032-08-08 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning September 9, 2022 until the option is fully vested on August 9, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 21:45 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,186 | $15.67 | $18,584.62 |
DisclosureSEC source: 0001209191-22-043961 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,172 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $15.32 and the highest price at which shares were sold was $16.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 21:45 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,207 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043961 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,895 Underlying: Common Stock · 3,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 21:45 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043961 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2022 Filed May 3, 2022 23:05 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,098 | $11.75 | $12,901.50 |
DisclosureSEC source: 0001209191-22-026892 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,151 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 30, 2022 Filed May 3, 2022 23:05 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026892 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,102 Underlying: Common Stock · 3,206 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2022 Filed May 3, 2022 23:05 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026892 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 846 shares of Common Stock acquired by the Reporting Person on February 15, 2022 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:14 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 51,308 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004401 · doc4.xml · derivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,308 Underlying: Common Stock · 51,308 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:14 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 115,438 | $0.00 Strike: $19.49 | $0.00 |
DisclosureSEC source: 0001209191-22-004401 · doc4.xml · derivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,438 Underlying: Common Stock · 115,438 shares Expires 2032-01-18 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001209191-22-000730 · doc4.xml · derivative · entry 5 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,905 Underlying: Common Stock · 1,428 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-22-000730 · doc4.xml · derivative · entry 4 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,466 Underlying: Common Stock · 400 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,828 | $28.96 | $52,938.88 |
DisclosureSEC source: 0001209191-22-000730 · doc4.xml · nonDerivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,428 | $9.57 | $13,665.96 |
DisclosureSEC source: 0001209191-22-000730 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 400 | $7.26 | $2,904.00 |
DisclosureSEC source: 0001209191-22-000730 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-067685 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,866 Underlying: Common Stock · 400 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $29.13 | $11,652.00 |
DisclosureSEC source: 0001209191-21-067685 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 400 | $7.26 | $2,904.00 |
DisclosureSEC source: 0001209191-21-067685 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:28 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-062466 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,266 Underlying: Common Stock · 400 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:28 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $33.24 | $13,296.00 |
DisclosureSEC source: 0001209191-21-062466 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:28 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 400 | $7.26 | $2,904.00 |
DisclosureSEC source: 0001209191-21-062466 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 23:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-061973 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,666 Underlying: Common Stock · 400 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 23:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $35.00 | $14,000.00 |
DisclosureSEC source: 0001209191-21-061973 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 23:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 400 | $7.26 | $2,904.00 |
DisclosureSEC source: 0001209191-21-061973 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-059064 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,066 Underlying: Common Stock · 400 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $29.92 | $11,968.00 |
DisclosureSEC source: 0001209191-21-059064 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 400 | $7.26 | $2,904.00 |
DisclosureSEC source: 0001209191-21-059064 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-055171 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,466 Underlying: Common Stock · 1,600 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,600 | $35.00 | $56,000.00 |
DisclosureSEC source: 0001209191-21-055171 · doc4.xml · nonDerivative · entry 2 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,600 | $7.26 | $11,616.00 |
DisclosureSEC source: 0001209191-21-055171 · doc4.xml · nonDerivative · entry 1 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:22 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-054434 · doc4.xml · derivative · entry 3 Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,066 Underlying: Common Stock · 400 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.